Oviva, a digital health company, transforming how we treat obesity and type 2 diabetes, has raised $21 million in Series B funding by new investor Earlybird, and existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures and Partech.
Oviva says it plans to use the capital to further develop its technology and fund it's continued expansion in Europe which will enable the company to serve more patients where the treatment is not currently available. The latest round of investment funding brings Oviva to a total of $34 million raised.
Oviva have developed unique, personalised behaviour change programmes that combine smartphone app and learning portal to support dietitian-led behaviour change for conditions which include type 2 diabetes and complex obesity.
Their approach allows patients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.
According to Oviva they have treated 90,000 patients in the last three years across the U.K., Germany, France, Switzerland and the UAE assisting patients with one-on-one coaching, evidence based learning materials together with progress tracking using smart app technology under the supervision of health care professional.
Oviva raises further $21 million in Series B funding to further develop it's type 2 diabetes and complex obesity treatment and for continued expansion into Europe providing treatment to patients where the treatment is not currently available.